Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
38.05
-0.19 (-0.50%)
Mar 13, 2025, 4:00 PM EST - Market closed
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 79.67, with a low estimate of 60 and a high estimate of 90. The average target predicts an increase of 109.38% from the current stock price of 38.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $73 → $75 | Strong Buy | Maintains | $73 → $75 | +97.11% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +91.85% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +91.85% | Jan 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $78 | Buy | Reiterates | $78 | +104.99% | Dec 30, 2024 |
Financial Forecast
Revenue This Year
1.05B
from 627.24M
Increased by 66.60%
Revenue Next Year
1.56B
from 1.05B
Increased by 49.28%
EPS This Year
-1.08
from -0.97
EPS Next Year
0.97
from -1.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.3B | 1.9B | 3.0B | ||
| Avg | 1.0B | 1.6B | 2.2B | ||
| Low | 842.8M | 1.2B | 1.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 99.3% | 77.5% | 94.7% | ||
| Avg | 66.6% | 49.3% | 43.5% | ||
| Low | 34.4% | 15.2% | 3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.62 | 1.29 | 0.96 | ||
| Avg | -1.08 | 0.97 | 0.93 | ||
| Low | -1.48 | 0.66 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | -1.4% | ||
| Avg | - | - | -4.2% | ||
| Low | - | - | -8.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.